Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Acorda Therapeutics, Inc. stock logo
ACOR
Acorda Therapeutics
$9.68
$0.61
$24.20
$820K1.4119,299 shs416,900 shs
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
$1.14
-2.6%
$1.17
$0.72
$6.45
$11.41M0.22389,647 shs98,008 shs
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
$7.77
-19.6%
$10.15
$3.60
$11.99
$106.19M0.4442,976 shs32,633 shs
Gamida Cell Ltd. stock logo
GMDA
Gamida Cell
$0.17
$0.03
$2.51
$5.04M0.939.20 million shs23.04 million shs
PolarityTE, Inc. stock logo
PTE
PolarityTE
$0.37
$0.20
$1.90
$1.78M1.15249,591 shs8.50 million shs
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Acorda Therapeutics, Inc. stock logo
ACOR
Acorda Therapeutics
0.00%0.00%0.00%0.00%0.00%
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
0.00%+7.55%+0.88%-0.88%-77.80%
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
0.00%+1.83%+20.19%+3.46%+53.25%
Gamida Cell Ltd. stock logo
GMDA
Gamida Cell
0.00%0.00%0.00%0.00%0.00%
PolarityTE, Inc. stock logo
PTE
PolarityTE
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Acorda Therapeutics, Inc. stock logo
ACOR
Acorda Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
4.1118 of 5 stars
3.54.00.04.70.60.80.6
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
4.3451 of 5 stars
3.53.00.04.40.62.51.3
Gamida Cell Ltd. stock logo
GMDA
Gamida Cell
N/AN/AN/AN/AN/AN/AN/AN/A
PolarityTE, Inc. stock logo
PTE
PolarityTE
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Acorda Therapeutics, Inc. stock logo
ACOR
Acorda Therapeutics
0.00
N/AN/AN/A
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
3.00
Buy$30.002,531.58% Upside
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
3.00
Buy$12.0054.44% Upside
Gamida Cell Ltd. stock logo
GMDA
Gamida Cell
0.00
N/AN/AN/A
PolarityTE, Inc. stock logo
PTE
PolarityTE
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Acorda Therapeutics, Inc. stock logo
ACOR
Acorda Therapeutics
$117.63M0.00N/A0.02($127.17) per share0.00
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
N/AN/AN/AN/A($1.36) per shareN/A
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
$50.15M2.14N/AN/A($0.14) per share-55.50
Gamida Cell Ltd. stock logo
GMDA
Gamida Cell
$1.78M0.00N/AN/A($0.02) per share0.00
PolarityTE, Inc. stock logo
PTE
PolarityTE
$810K0.00N/AN/A$2.30 per share0.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Acorda Therapeutics, Inc. stock logo
ACOR
Acorda Therapeutics
-$252.85M-$203.83N/AN/AN/A-214.95%-2,206.93%-83.28%N/A
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
-$11.62M-$3.36N/AN/AN/AN/AN/A-519.50%8/13/2025 (Estimated)
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
-$7.28M-$0.0617.66N/A10.97%656.65%24.04%N/A
Gamida Cell Ltd. stock logo
GMDA
Gamida Cell
-$63M-$0.63N/AN/AN/AN/AN/A-57.59%N/A
PolarityTE, Inc. stock logo
PTE
PolarityTE
-$7.83M-$3.28N/AN/AN/AN/A-106.08%-76.91%N/A

Latest PTE, ACOR, BCLI, CSBR, and GMDA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
-$0.38-$0.45-$0.07-$0.45N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Acorda Therapeutics, Inc. stock logo
ACOR
Acorda Therapeutics
N/AN/AN/AN/AN/A
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
N/AN/AN/AN/AN/A
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
N/AN/AN/AN/AN/A
Gamida Cell Ltd. stock logo
GMDA
Gamida Cell
N/AN/AN/AN/AN/A
PolarityTE, Inc. stock logo
PTE
PolarityTE
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Acorda Therapeutics, Inc. stock logo
ACOR
Acorda Therapeutics
3.07
0.33
0.26
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
N/A
0.21
0.21
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
N/A
0.99
0.99
Gamida Cell Ltd. stock logo
GMDA
Gamida Cell
213.14
2.16
2.09
PolarityTE, Inc. stock logo
PTE
PolarityTE
N/A
4.11
4.11

Institutional Ownership

CompanyInstitutional Ownership
Acorda Therapeutics, Inc. stock logo
ACOR
Acorda Therapeutics
12.71%
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
14.33%
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
41.30%
Gamida Cell Ltd. stock logo
GMDA
Gamida Cell
50.34%
PolarityTE, Inc. stock logo
PTE
PolarityTE
11.75%
CompanyEmployeesShares OutstandingFree FloatOptionable
Acorda Therapeutics, Inc. stock logo
ACOR
Acorda Therapeutics
1111.24 million1.21 millionNo Data
Brainstorm Cell Therapeutics Inc. stock logo
BCLI
Brainstorm Cell Therapeutics
409.84 million8.74 millionOptionable
Champions Oncology, Inc. stock logo
CSBR
Champions Oncology
14313.83 million7.33 millionOptionable
Gamida Cell Ltd. stock logo
GMDA
Gamida Cell
143154.05 million143.70 millionOptionable
PolarityTE, Inc. stock logo
PTE
PolarityTE
427.38 million6.98 millionOptionable

Recent News About These Companies

Regenetp Inc RGTPQ
RegenETP, Inc. (NJT.SG)
PolarityTE Inc. [PTE] Investment Appeal on the Rise
PolarityTE Stock (NASDAQ:PTE), Dividends
Form DEF 14A ENERGY FUELS INC - StreetInsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Acorda Therapeutics stock logo

Acorda Therapeutics NASDAQ:ACOR

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. The company's product pipeline includes Cimaglermin alfa (GGF2), a member of neuregulin growth factor family which is in Phase 1 clinical trials for recovery of neurological injury, as well as to enhance heart function in animal models of heart failure. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. The company was incorporated in 1995 and is headquartered in Pearl River, New York.

Brainstorm Cell Therapeutics stock logo

Brainstorm Cell Therapeutics NASDAQ:BCLI

$1.14 -0.03 (-2.56%)
Closing price 07/3/2025 03:55 PM Eastern
Extended Trading
$1.15 +0.01 (+1.23%)
As of 07/3/2025 04:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.

Champions Oncology stock logo

Champions Oncology NASDAQ:CSBR

Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ.

Gamida Cell stock logo

Gamida Cell NASDAQ:GMDA

Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with hematologic malignancies, as well as in Phase II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, an investigational NK cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was incorporated in 1998 and is headquartered in Jerusalem, Israel.

PolarityTE stock logo

PolarityTE NASDAQ:PTE

PolarityTE, Inc., a clinical stage biotechnology company, develops and commercializes a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. The company operates in two segments, Regenerative Medicine Products and Contract Services. It offers SkinTE, a tissue product used to repair, reconstruction, replacement, and supplementation of skin in patients for the treatment of acute or chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts, as well as contract research services. The company also develops SkinTE Cryo allows multiple deployments from one original harvest through a cryopreservation process; SkinTE point-of-care device to permit the processing and deployment of SkinTE immediately following the initial harvest at the point-of-car; and other tissue regeneration products. PolarityTE, Inc. is headquartered in Salt Lake City, Utah.